TICKERNERD
Menu
MOBIHealthcare · Medical Devices

MOBI Stock Forecast: Mobia Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$11
−3.11% on the day

The 4 Wall Street analysts covering Mobia Medical, Inc. hold a median 12-month price target of $18 — +69.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$352.8M
Ticker Nerd rank
2 / 100
Median analyst target
$18
Analysts covering
4
Total return, dividends reinvested
1W
−9.8%
1M
−11.5%
From high
−27.5%
From low
+1.7%
$10
$15
Range since 8 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

MOBI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mobia Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
59
Revisions
41
Momentum
8
Growth
8
Accruals
8
Issuance
6
Value
3
Volatility
1
Quality
1

Size (59): Smaller than most of the companies we track.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MOBI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MOBI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 May 2026Adjusted close, US dollars
$10$12$14$16$18$20Jun 26Jul 26Aug 26MOBIHigh $19Median $18Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $16Median $18High $19

The green dot is the last close — the median target sits +69.7% from it.

Recent analyst actionsNewest first

Of the 10 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
12 Aug 2026BTIGReiteratesBuy$19
12 Aug 2026JP MorganMaintainsOverweight$15 → $17
2 June 2026B of A SecuritiesInitiatesBuy$16
2 June 2026BTIGInitiatesBuy$19
2 June 2026Goldman SachsInitiatesBuy$31
2 June 2026JP MorganInitiatesOverweight$15
26 Feb 2015RosenblattInitiatesBuy$10
4 Feb 2013Piper SandlerMaintainsOverweight$2.94 → $2.70
12 Nov 2012Piper SandlerMaintainsOverweight$3.20 → $2.94
14 Aug 2012Piper SandlerMaintainsOverweight$7.00 → $3.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MOBI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MOBI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Mobia Medical, Inc. (MOBI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−528.5×

Cheaper than 99% of US stocks

Price / sales
7.8×

Cheaper than 17% of US stocks

Price / book
−2.1×

Cheaper than 95% of US stocks

EV / EBITDA
−3.1×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
102.4%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
82.3%

Higher than 92% of US stocks

Operating margin
−132.7%

Higher than 12% of US stocks

Net margin
−141.6%

Higher than 4% of US stocks

Returns & dividend
Return on equity
30.8%

Higher than 88% of US stocks

Return on assets
−96.6%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MOBI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MOBIMobia Medical, Inc.$352.8M
2
VMDViemed Healthcare, Inc.$336.5M
96
ELMDElectromed, Inc.$329.0M
99
CATXPerspective Therapeutics, Inc.$375.9M
30
TLSITriSalus Life Sciences, Inc.$315.2M
29
OFIXOrthofix Medical, Inc.$396.4M
81
RCELAVITA Medical, Inc.$306.8M
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mobia Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MOBI news & analysis

Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Mobia Medical, Inc. (MOBI) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and associated discussion.

Why it matters — Investors and analysts following MOBI would review the earnings call transcript for details on the company's second-quarter 2026 financial performance and management commentary.

Mobia Medical Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

Mobia Medical reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, driven by expanded adoption of its Vivistim paired vagus nerve stimulation therapy across new and existing stroke-care programs as discussed in its Q2 earnings call.

Why it matters — For MOBI watchers, the 102% revenue growth signals strong uptake of the Vivistim therapy across expanded stroke-care programs.

Mobia Medical Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 11 Aug 2026positive

Mobia Medical reported financial results for the quarter ended June 30, 2026, with revenue of $13.5 million representing 102% year-over-year growth and a gross margin of 83.2%. The company also announced publication of two-year VNS-REHAB follow-up data in Neurology, completed its initial public offering with approximately $134.0 million in net proceeds, and appointed Myriam Curet, M.D.

Why it matters — The quarterly update provides MOBI watchers with the company's revenue growth, margin performance, and clinical data milestones as a newly public medical device company.

FAQ

Frequently asked questions about MOBI stock

What is the MOBI stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Mobia Medical, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MOBI stock a buy right now?

Of the 4 analysts covering Mobia Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mobia Medical, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MOBI?

As at 22 Aug 2026, Mobia Medical, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (59 of 100).

Will MOBI stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +69.7% from the last close, and Ticker Nerd's factor model ranks Mobia Medical, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MOBI stock forecast for 2030?

No analyst covering Mobia Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MOBI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $19 over the next 12 months.

What does Mobia Medical, Inc. do?

Mobia Medical, Inc. is a commercial-stage medical device company focused on redefining stroke recovery for survivors with moderate to severe upper extremity motor impairments.

What is the latest news on MOBI?

The most recent item we track (Seeking Alpha, 11 Aug 2026): "Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript". Mobia Medical, Inc. (MOBI) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and associated discussion.

Company

About Mobia Medical, Inc.

Mobia Medical, Inc. is a commercial-stage medical device company focused on redefining stroke recovery for survivors with moderate to severe upper extremity motor impairments. Its flagship product, the Vivistim Paired VNS System, is the first and only FDA-approved implantable solution that pairs targeted vagus nerve stimulation with functional movement exercises to promote neuroplasticity and enhance upper limb function in chronic ischemic stroke patients. This innovative therapy addresses a critical gap in post-stroke rehabilitation by driving meaningful, lasting improvements in motor recovery. Mobia Medical, Inc. supports patients, healthcare providers, and care partners through its commercial operations, emphasizing accessible stroke care solutions. The company operates within the neurostimulation and rehabilitation medical device sector, targeting the needs of chronic stroke survivors. Founded in 2007 and headquartered in Austin, Texas, Mobia Medical, Inc. plays a pivotal role in advancing therapeutic options for neurological recovery in the medical technology market.

CEO Mr. Richard John Foust · 167 employees · United States · https://www.mobia.com